WestPark Capital initiated coverage of Akebia Ther (AKBA) at Buy on September 8, 2026.
Among three firms active over the past 90 days, three hold a bullish rating. As of October 30, 2026, seven analysts place the consensus mean at $3.57, the median at $4.08 and the range at $1.01 to $4.73.
The Q4 FY2026 consensus calls for -$0.04 in EPS on $49.15 million in revenue. The next earnings date is February 24, 2027.
